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Abstract: Early detection of people with undiagnosed type 2 diabetes (T2D) is an important public
health concern. Several predictive equations for T2D have been proposed but most of them have not
been externally validated and their performance could be compromised when clinical data is used.
Clinical practice guidelines increasingly incorporate T2D risk prediction models as they support
clinical decision making. The aims of this study were to systematically review prediction scores for
T2D and to analyze the agreement between these risk scores in a large cross-sectional study of white
western European workers. A systematic review of the PubMed, CINAHL, and EMBASE databases
and a cross-sectional study in 59,042 Spanish workers was performed. Agreement between scores
classifying participants as high risk was evaluated using the kappa statistic. The systematic review of
26 predictive models highlights a great heterogeneity in the risk predictors; there is a poor level of
reporting, and most of them have not been externally validated. Regarding the agreement between
risk scores, the DETECT-2 risk score scale classified 14.1% of subjects as high-risk, FINDRISC score
20.8%, Cambridge score 19.8%, the AUSDRISK score 26.4%, the EGAD study 30.3%, the Hisayama
study 30.9%, the ARIC score 6.3%, and the ITD score 3.1%. The lowest agreement was observed
between the ITD and the NUDS study derived score (κ = 0.067). Differences in diabetes incidence,
prevalence, and weight of risk factors seem to account for the agreement differences between scores.
A better agreement between the multi-ethnic derivate score (DETECT-2) and European derivate scores
was observed. Risk models should be designed using more easily identifiable and reproducible health
data in clinical practice.
Keywords: diabetes mellitus; type 2 diabetes; risk scales; risk scores; prediction model;
systematic review
1. Introduction
Type 2 diabetes (T2D) is a common disease associated with reduced life expectancy and
considerable morbidity [1]. Furthermore, T2D is commonly an asymptomatic condition [2] associated
with other non-communicable diseases, and causes a high number of hospitalizations and a significant
economic impact [3,4]. According to the International Diabetes Federation (Diabetes Atlas 2019), the
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prevalence of diabetes is increasing worldwide, and it is estimated to increase from 9.3% to 10.9% by
2045, affecting 700 million adults [5]. In addition, about 50% of all people with diabetes worldwide are
not diagnosed [1]. Diabetes prevalence varies among regions, ranging from 5% to 20%, with a higher
incidence in Oceania, the Caribbean, South Asia, the Middle East, Latin America, and Central Asia [6].
Early detection of people with undiagnosed T2D is an important public health concern, as up to
half of people with newly diagnosed T2D present one or more complications when it is diagnosed [7,8].
Several large clinical trials have shown that diabetes could be prevented by recommending lifestyle
changes such as advocating physical activity, a healthy low fat diet and weight reduction [3,9,10].
These lifestyle changes have been shown to decrease the risk of diabetes by nearly 60% [9,11–14]. Thus,
policies focusing on diabetes prevention and early identification of T2D in populations at high risk may
be worth seriously considering [15]. Furthermore, some studies show how some diabetes risk scores,
such as the German Diabetes Risk Score (GDRS) or the Atherosclerosis Risk in Communities model
(ARIC 2009), allow the identification of high-risk target groups for cost-effective lifestyle interventions
to prevent T2D [16].
The worldwide number of published risk prediction tools for identifying individuals at risk of
T2D has greatly increased in the last few years [15,17,18]. However, there is no consensus on which is
the best risk score and only a few of them end up being used in clinical practice. Prognostic risk-score
models for T2D vary from those including only clinical variables to those with a genetic score and
biochemical markers. These risk scores have been derived over a wide range of different populations.
T2D risk scores should be externally validated using data from different settings, populations,
and ethnics groups, because generalization outside of the context in which they were designed could
affect their performance and therefore, their external usefulness [18]. A review and external validation
of commonly used prediction tools including only clinical and conventional biomarkers demonstrated
that risk prediction tools work properly in the validation cohorts [19]. However, most of the models
overestimate the number of people at high risk. These fitting differences could be explained by
differences in population baseline characteristics and in the methodology used [20–23]. Furthermore,
ethnicity or diabetes incidence could play an important role in the differences between risk scores [24].
The aims of this study were to systematically review predictive T2D equations and to analyze the
agreement between these prediction risk scores in a cross-section study of Spanish Caucasian workers.
Risk scores derived from populations with very different characteristics such as distinct ethnicities and
a wide range of diabetes incidence were considered.
2. Material and Methods
2.1. Search Strategy
Articles that presented new risk prediction models for detecting T2D were identified. A systematic
review was performed in Medline, PubMed, CINAHL, and EMBASE databases following PRISMA
guidelines [25] looking for articles that reported models or predictive equations for incident diagnosis
of T2D until July 2018. The following search string was used: ((“diabetes mellitus” OR “type 2
diabetes” OR “diabetes”) AND (“predictive model” OR “predictive equation” OR “prediction model”
OR “prediction rule” OR “risk assessment” OR “risk score”) NOT (“review” OR “bibliography”)).
Articles were restricted to English, Portuguese, and Spanish language literature. Reference lists was
also verified for relevant citations. The search strategy was performed in cooperation with a research
librarian. Unpublished literature was identified through the Information System on Gray Literature in
Europe (Open Gray), Conference Proceedings of the Web of Science and ProQuest Dissertations, and
Theses Global.
References of the studies identified by the literature search strategy were imported into EndNote
X9 (Clarivate Analytics, Philadelphia, PA, USA) literature management software, and duplicates were
removed. One researcher (A.A.) screened for the titles and abstracts of all articles identified by the
search string to exclude articles that did not report risk prediction models. After reviewing the retrieved
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titles, to ensure the quality of the process, two additional authors (J.A.A.-V. and M.B.-V.) independently
reviewed the abstracts to select the relevant papers. Each article was randomly assigned to reviewers.
Discrepancies between reviewers were solved by a third reviewer (A.L.). To reduce the risk of bias,
a pilot exercise was carried out to apply the inclusion criteria in a sample of 10 references.
Study characteristics and study data was managed using Microsoft Excel 2013 (Microsoft Corp,
Redmond, WA, USA, www.microsoft.com) and Review Manager software (RevMan version 5.3,
Copenhagen, Denmark: The Nordic Cochrane Centre, the Cochrane Collaboration 2014), respectively.
A standardized form was used for data extraction, including general information (author(s), journal,
location, year, country, and conflict of interest); population characteristics (age, sex, ethnicity, and
inclusion and exclusion criteria); and study details (study design, sample size, statistical analysis,
and bias). Articles where the model/equation included genetic testing or non-common biomarkers
were excluded.
2.2. Study Design
A cross-sectional study with Caucasian western European adult workers (aged 20–65 years)
was performed. All subjects were from a Spanish Mediterranean area and belonged to different
productive sectors (public administration, health department, and the post office). Study design,
procedures and reporting followed guidance from the STROBE statement on observational studies [26].
To evaluate the correlation of the retrieved prediction models, the original published prediction
models were used (scores or original regression equations). Then, participants’ risk of developing
T2D was determined using the following models: diabetes and impaired glucose tolerance score
(DETECT-2) [27]; Danish Diabetes Risk Score (DDRS) [28]; data from the epidemiological study on the
insulin resistance syndrome score (DESIR) [29]; Cambridge risk score [30]; QDScore [31]; FINDRISC
score [32]; EGAT score [33]; Australian T2D risk score (AUSDRISC) [34]; instrument for T2D score
(ITD) [35]; atherosclerosis risk in communities score (ARIC) [36]; San Antonio prediction model risk
score [37]; Framingham offspring score [38]; diabetes population risk tool score (DPoRT) [39]; scores
from Oman [40], India (IDRS) [41], Taiwan [42], and Kyushu island of Japan [43]; and scores from
military officers of China [44], and Mauritian Indians [45]. Six predictive models selected in the
systematic review were not included to analyze the correlation with the equation because it was
impossible to calculate the score in the German Diabetes Risk Score (GDRS) [46] and the modified
GDRS [47] because diet was not ascertained in our population. The Tromsø Study [48], the Mauritan
Indians risk score [45], the Tehran lipid and glucose studies [49], and the AusDiab [50] general scores
were not determined because the original paper did not report enough data to allow proper score
calculations. Agreement between results was analyzed as it is indicated in the statistical analysis section.
2.3. Participants and Recruitment
Participants in the study were recruited during their periodic health examination in the workplace
between January 2008 and December 2010. Every day each worker was assigned a number, and
half of the examined workers were randomly selected using a random number table. Thus, from
a total population of 130,487 workers, 65,200 were invited to participate in the study. 14,946 (22.9%)
refused to participate, leaving the final number of participants standing at 590,424 (77.1%), with 25,510
women (43.2%), and 33,532 men (56.8%). The mean age of the participants in the study was 39.7 years
(SD 10.2). All participants were informed of the purpose of this study before they provided written
informed consent to participate. Following the current legislation, members of the Health and Safety
Committees were informed as well. The study protocol was in accordance with the Declaration of
Helsinki and was approved by the Institutional Review Board of the Mallorca Health Management
(GESMA). After acceptance, a self-reported complete medical history, including family and personal
history, was recorded. The following inclusion criteria were considered: age between 18 and 65 years
(working age population), being gainfully employed, and without a previous diagnosis of diabetes.
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Subjects who did not meet any of the inclusion criteria and those who refused to participate were
excluded from the study.
2.4. Samples and Measurements
The methodology used was similar to the one previously reported [51]. Anthropometric
measurements were made in the morning at the same time, and according to the recommendations of the
International Standards for Anthropometric Assessment (ISAK) [52]. Furthermore, all measurements
were performed by well-trained technicians or researchers to minimize coefficients of variation. Body
weight (electronic scale Seca 700 scale, Seca GmbH, Hamburg, Germany), height (stadiometer Seca
220 CM Telescopic Height Rod for Column Scales, Seca GmbH, Hamburg, Germany), and abdominal
waist circumference using a Lufkin Executive® Thinline, precision 1 mm (Lufkin Executive Thinline,
W606PM, Cooper Industries, Lexington, SC, USA) were determined according to the aforementioned
recommended techniques. Body mass index (BMI) was calculated as weight (kg) divided by height (m)
squared. Waist circumference was measured halfway between the lower costal border and the iliac
crest. The measurement was made at the end of a normal expiration while the subject stood upright,
with feet together and arms hanging freely at their sides.
Venous blood samples were taken after participants were seated at rest for at least 15 min from
the antecubital vein with suitable vacutainers without anticoagulant to obtain serum. Blood samples
were taken following a 12 h overnight fast. Concentrations of glucose, cholesterol and triglycerides
were measured in serum by standard clinical biochemistry laboratory procedures using an automated
hematology analyzer (SYNCHRON CX®9 PRO, Beckman Coulter, Brea, CA, USA).
2.5. Statistical Analysis
Descriptive analysis was used to report the frequency and distribution of categorical variables,
whereas means and standard deviations (SDs) were reported for quantitative variables. The Spearman
correlation coefficients were used to analyze the correlation between prediction scores of T2D.
Participants were classified as high risk for developing diabetes if the cut-off points were reported
in the publication; the following cut-off points were considered for classifying people at high risk:
31 points out of 60 in the Danish Diabetes Risk Score (DDRS); 7 points out of 32 in the Diabetes and
Impaired Glucose Tolerance score (DETECT-2); 0.37 out of 1 point in the Cambridge score; a score of
over 6 out of 20 in the FINDRISC; over 12 out of 43 in the Australian T2D Risk (AUSDRISK); over 60
out of 100 in the Indian Diabetes Risk Score (IDRS); over 6 out of 17 in the Electric Generating Authority
of Thailand Study (EGATS); over 14 out of 49 in the Hisayama study; over 21 out of 40 in the National
Urban Diabetes Survey (NUDS); and 55 out of 100 in the instrument for T2D (ITD). Agreement between
2 by 2 charts of participants classified as high risk was assessed using the kappa statistic. Statistical
analyses were performed using IBM SPSS Statistics version 24 (SPSS/IBM, Chicago, IL, USA).
3. Results
The literature search strategy retrieved 820 original articles, 42 of which met the inclusion criteria
considered (Figure 1).
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Oceania) [27]. 
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hypertensive patients [64,65], validation studies [66,67], and those considering scores that include 
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Figure 1. Flow diagram of selected studies.
The summarized characteristics of the studies included in the review are shown in Table 1. We
selected prediction tools developed from adult or middle adult populations that include predictors
generally available in health records (demographics, history of parental diabetes or gestational diabetes,
obesity, diet, lifestyle factors, obesity, antihypertensive medication, use of corticoids) as well as
conventional biomarkers such as glucose, HDL-cholesterol, LDL-cholesterol, and triglycerides.
There were 26 papers from six continents, 9 prioritizing scores from Europe [28–32,46–48,53],
9 from Asia [33,40–45,49,54], 2 from Oceania [34,50], 1 from South-America [35], 5 from
North-America [36–39,55] and finally one including populations or participants from 3 continents
(Africa, Asia, and Oceania) [27].
Table 2 summarizes the characteristics of the excluded studies: those reporting the calibration
of selected prediction tools [56–61], performed in an elderly population [62,63], only in men or
hypertensive patients [64,65], validation studies [66,67], and those considering scores that include
biomarkers or genotype determinations that are not easily available for clinicians [68–73].
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Table 1. Models included for predicting risk of incident type 2 diabetes.
Author/Year Population Risk Predictors Name RiskDiabetes Score Risk Predictors in the Model Country
% Incidence
Diabetes




Glumer 2004 [28] Adults30–64 years Clinical DDRS
Age, gender, body mass index, known hypertension,






Balkau 2008 [29] Adults volunteers30–65 years Clinical DESIR
Men: Waist circumference, hypertension, smoking status
Women: Waist circumference, family history of diabetes,
hypertension
western French 7.5
Schulze 2007 [46] Adults35–65 years Clinical and diet GDRS
Age, waist circumference, height, history of hypertension,
physical inactivity, smoking, consumption of red meat,






35–65 years Clinical and diet GDRS-modified
Age, waist circumference, height, history of hypertension,
physical, inactivity, smoking, consumption of red meat,
whole grain bread, coffee, alcohol and history of diabetes
German
(Epic-Potsdam) 2.2
Simmons 2007 [53] Adults40–79 years Clinical and diet EPIC-Norfolk
Age, gender, physical activity, family history of diabetes,
BMI, smoking whole grain bread, fruits UK (Epic-Norfolk) 1.7
Rahman 2008 [30] Adults40–79 years Clinical Cambridge
Age, gender, current use of corticosteroids, use of











Age, gender, ethnicity, BMI, smoking, family history of
diabetes, Townsend score, treated hypertension,
cardiovascular disease, current use of corticosteroids
England (3–4% of
another ethnicity) 3.1
Lindstrom 2013 [32] Adults35–64 years Clinical FINDRISC
Age, BMI, waist circumference, use of antihypertensive
drugs, history of hypertension
Finland National
Population Register 4.1
Joseph 2010 [48] Adults25–98 years
Clinical and
biological The Tromsø Study
Age, BMI, total cholesterol, triglyceride level, high density
lipoprotein cholesterol level, hypertension, family history
of diabetes, education, physical inactivity, smoking
North Norway 2.0
Asia
Aekplakorn 2006 [33] Adult workers35–55 years Clinical EGATS
Age, BMI, waist circumference, hypertension, family
history of diabetes in first degree relative Thailand 11.1
Al-Lawati 2007 [40] Adults
>20 years Clinical Omani
Age, BMI, waist circumference, hypertension, family
history of diabetes, current hypertension status Oman
prevalent
cases




FPG, 2hPLG, TG, PAS, HDL-C and family history of
diabetes Iran 10.1
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Table 1. Cont.
Author/Year Population Risk Predictors Name RiskDiabetes Score Risk Predictors in the Model Country
% Incidence
Diabetes
Mohan 2005 [41] Adults
>18 years Clinical IDRS
Age, waist circumference, hypertension, family history of




>20 year Clinical NUDS




Gao 2009 [45] Adults20–65 years Clinical NS BMI, waist circumference, family history of diabetes Mauritians Indian 16.5
Liu 2011 [44] Adults40–90 years
Clinical and
biological MJLPD
Age, hypertension, history of high blood glucose level,
BMI, fasting plasma glucose level, triglyceride level, high
density lipoprotein cholesterol level
Military officer in
Beijing, China 26.6
Chuang 2011 [42] Adults
>35 years Clinical Chinese-DRS Age, gender, education, alcohol, BMI, waist circumference Taiwan 6.5
DoI 2012 [43] Adults40–79 years Clinical Hisayama study
Age, gender, family history of diabetes, abdominal
circumference, body mass index, hypertension, regular








Age, gender, ethnicity, fasting plasma glucose level,
systolic blood pressure, high density lipoprotein
cholesterol level, BMI, parental history of diabetes
Australian main
Caucasian 3.8
Chen 2010 [34] Adults
>25 years Clinical AUSDRISK
Age, gender, BMI, ethnicity, physical inactivity, smoking,
history of high blood pressure, use of antihypertensive









Age, gender, family history of diabetes, family history of
hypertension, family history of obesity, history of
gestational diabetes or macrosomia, fasting plasma glucose
level, physical inactivity, triglyceride level, systolic or
diastolic blood pressure, BMI
México 14.1
North-America
Schmidt 2005 [36] Adults45–64 years
Clinical and
biological ARIC
Age, waist circumference, height, systolic blood pressure,
family history of diabetes, ethnicity, fasting plasma glucose
level, HDL, Triglycerides
US 16.3
Stern 2002 [37] Adults25–64 years
Clinical and
biologicals San Antonio
Age, gender, ethnicity, fasting plasma glucose level, systolic
blood pressure, high density lipoprotein cholesterol level,
BMI, family history of diabetes in first degree relative
US (61% Mexican
Americans) 9.2
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Table 1. Cont.
Author/Year Population Risk Predictors Name RiskDiabetes Score Risk Predictors in the Model Country
% Incidence
Diabetes
Wilson 2007 [38] Middle aged Clinical andbiological
Framingham
Offspring
Fasting plasma glucose level, BMI, high density lipoprotein
cholesterol level, parental history of diabetes, triglyceride
level, blood pressure
US (Framingham) 5.1
Kahn 2009 [55] Adults Clinical andbiological ARIC enhanced
Family history of diabetes (mother or father), hypertension,
ethnicity, age, alcohol, waist circumference, height, resting
pulse, glucose level, triglycerides, HDL cholesterol, uric
acid
US 19.0
Rosella 2011 [39] Adults
>20 years Clinical DPoRT
Age, ethnicity, BMI, hypertension, immigrant status,
smoking, education, cardiovascular disease Ontario Canada 7.1
DETECT-2: Diabetes and Impaired Glucose Tolerance; DDRS: Danish Diabetes Risk Score; DESIR: Data from the Epidemiological Study on the Insulin Resistance Syndrome; GDRS:
German Diabetes Risk Score; EPIC-Norfolk: European Prospective Investigation of Cancer and Nutrition; Cambridge: Cambridge Risk Score; FINDRISC: Finnish Diabetes Risk Score;
EGATS: Electric Generating Authority of Thailand Study; IDRS: The Indian Diabetes Risk Score; NUDS: National Urban Diabetes Survey; MJLPD: MJ Longitudinal health-check-up-based
Population Database; Chinese-DRS: Chinese Diabetes Risk Score; AusDiab: Australian Diabetes, Obesity and Lifestyle study; AUSDRISK: Australian Type 2 Diabetes RISK; ITD: Instrument
for type 2 diabetes (ITD); ARIC: Atherosclerosis Risk in Communities; San Antonio: San Antonio prediction model; Framingham offspring: Framingham Offspring Score; DPoRT: Diabetes
Population Risk Tool.
Table 2. Models excluded for predicting risk of incident type 2 diabetes.
Author/Year Name Risk Diabetes Risk Predictors in the Model Reason for Exclusion
Alssema 2008 [56] PREVEND (Modified FINDRISC for Dutchpopulation)
Age, BMI, waist circumference, use of antihypertensive drugs, history of
gestational diabetes Calibration of FINDRISC
Von Eckardstein 2000 [65] PROCAM score Age, BMI, hypertension, glucose, family history of diabetes, high densitylipoprotein cholesterol level Only men
Bozorgmanesh 2013 [57] Modified ARIC-Teheran
Family history of diabetes, systolic blood pressure, waist–height ratio,
triglyceride-high density lipoprotein ratio, fasting plasma glucose level,
two-hour postprandial plasma glucose level
Calibration of ARIC
Chien 2009 [58] Cambridge Risk score -Taiwan Age, BMI, white blood cell count, triglyceride level, high density,lipoprotein cholesterol level, fasting plasma glucose level
Calibration of Cambridge score
in Taiwanese population
McNeely 2003 [66]
Age, sex, ethnicity, BMI, systolic blood pressure, fasting plasma glucose
level, high density lipoprotein cholesterol level, family history of diabetes
in first degree relative
Validation study
Wong 2013 [73] Sex, age, systolic blood pressure, waist, total cholesterol, HDL-C,triglycerides and HbA1c Include complex biomarkers
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Table 2. Cont.
Author/Year Name Risk Diabetes Risk Predictors in the Model Reason for Exclusion
Gupta 2008 [64]
Fasting Plasma Glucose (FPG), history of diabetes and drug or dietary
therapy for diabetes. Presence of both impaired FPG (>6 and <7 mmol/L)
and glycosuria
Only hypertensive population
Ku 2013 [60] Findrisk in a Philippine population Age, BMI, waist circumference, use of antihypertensive drugs, history ofhypertension Calibration Find Risk
Kanaya 2005 [63] Age, sex, triglyceride level, fasting plasma glucose level Old adults
Kolberg 2009 [68] Inter99 Six biomarkers: adiponectin, C reactive protein, ferritin, glucose,interleukin 2 receptor A, insulin Include complex biomarkers
Chin 2012 [59] The ARIC predictive model reliably predictedrisk of type 2 diabetes in Asian populations
Waist circumference, parental history of diabetes, hypertension, short
stature, black race, age, weight, pulse, smoking Calibration ARIC
Guasch-Ferré 2012 [62]
A risk score to predict type 2 diabetes mellitus
in an elderly Spanish Mediterranean
population
BMI, smoking status, family history of type 2 diabetes, alcohol
consumption and hypertension Old adults
Vassy 2012 [72] Genotype prediction of adult type 2 diabetesfrom adolescence in a multiracial population
Demographics, family history, physical examination, routine biomarkers,
and 38 single-nucleotide polymorphism diabetes genotype score
Include a genotype score to
predict diabetes
Raynor 2013 [70]
Novel risk factors and the prediction of type 2
diabetes in the Atherosclerosis Risk in
Communities (ARIC) study
Adiponectin, leptin, γ-glutamyl transferase, ferritin, intercellular adhesion
molecule 1, complement C3, white blood cell count, albumin, activated
partial thromboplastin time, factor VIII, magnesium, hip circumference,
heart rate, and a genetic risk score
Include genotype
Sun 2009 [61] The ARIC predictive model reliably predictedrisk of type 2 diabetes in Taiwanese population
Waist circumference, parental history of diabetes, hypertension, short
stature, black race, age, weight, pulse, smoking Calibration of ARIC
Meigs 2008 [69]
Age, sex, family history of diabetes, BMI, triglyceride level, fasting plasma
glucose level, systolic blood pressure, high density lipoprotein cholesterol
level and genotype score
Include genotype
Nichols 2008 [67]
Age, sex, parental history of diabetes, BMI, hypertension or
antihypertensive drugs, high density lipoprotein cholesterol level,
triglyceride level, fasting plasma glucose level
Validation of the Framingham
Offspring Study equations
Urdea 2009 [71] PreDx diabetes risk score Levels of adiponectin, C reactive protein, ferritin, glucose, hemoglobinA1c,interleukin 2, insulin Include complex biomarkers
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In the cross-sectional study, risk of developing T2D was determined in a large sample of workers
(n = 59,042). Correlations between the retrieved prediction models were evaluated using the original
published scores or original regression equations. Agreement between predictions risk scores was
analyzed as well. Table 3 summarizes the characteristics of participants in the study.
Table 3. Baseline participants’ characteristics (n = 59,042).
Mean (SD)/n (%)
Age (years) 39.7 ± 10.2
Men 33,532 (56.8)
Smoking 20,612 (34.9)
Body Mass Index (kg/m2) 26.0 ± 4.6
Waist circumference (cm) 82.7 ± 11.6
Systolic blood pressure (mmHg) 120.3 ± 16.0
Diastolic blood pressure (mmHg) 73.4 ± 10.9
Cholesterol (mg/dL) 194.7 ± 37.7
High-density lipoproteins (mg/dL) 52.6 ± 8.5
Low-density lipoproteins (mg/dL) 121.2 ± 37.1
Triglycerides (mg/dL) 107.6 ± 73.0
Fasting plasma glucose (mg/dL) 86.4 ± 12.0
Table 4 shows the Spearman correlation coefficients of the models. There is a wide range of
correlation values, from low to high values of correlation. For example, correlations considering the
Cambridge score range from 0.560 to 0.898, and correlations including the Framingham offspring range
from 0.481 to 0.760. Table 5 shows the agreement (kappa) between risk predicted (high and non-high
risk) and Table S1 (Supplementary Material) shows the distribution of the population into high risk
and non-high risk groups. Agreements found between the classifications using the different scores
ranged from 0.412 (between the ARIC and the DESIR score) to 0.916 (between AUSDRISK and the
Hisayama study).
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Table 4. Correlation between models included for predicting risk of type 2 diabetes.











DETECT-2 1 0.754 ** 0.779 ** 0.842 ** 0.762 ** 0.793 ** 0.761 ** 0.680 ** 0.668 ** 0.710 ** 0.780 ** 0.574 ** 0.807 ** 0.862 ** 0.591 ** 0.500 ** 0.579 ** 0.585 ** 0.829 ** 0.616 **
DDRS 0.754 ** 1 0.515 ** 0.881 ** 0.926 ** 0.872 ** 0.832 ** 0.881 ** 0.866 ** 0.911** 0.851** 0.659 ** 0.831 ** 0.777 ** 0.826 ** 0.595 ** 0.691 ** 0.691 ** 0.894 ** 0.609 **
DESIR 0.779 ** 0.515 ** 1 0.634 ** 0.541 ** 0.611 ** 0.629 ** 0.519 ** 0.562 ** 0.522 ** 0.712 ** 0.535 ** 0.711 ** 0.775 ** 0.464 ** 0.412 ** 0.443 ** 0.481 ** 0.598 ** 0.519 **
Cambridge 0.842 ** 0.881 ** 0.634 ** 1 0.898 ** 0.777 ** 0.814 ** 0.754 ** 0.794 ** 0.823 ** 0.848 ** 0.639 ** 0.865 ** 0.838 ** 0.683 ** 0.560 ** 0.705 ** 0.644 ** 0.864 ** 0.560 **
QDScore 0.762 ** 0.926 ** 0.541 ** 0.898 ** 1 0.807 ** 0.854 ** 0.854 ** 0.820 ** 0.893 ** 0.846 ** 0.642 ** 0.793 ** 0.736 ** 0.767 ** 0.592 ** 0.694 ** 0.638 ** 0.853 ** 0.582 **
FINDRISC 0.793 ** 0.872 ** 0.611 ** 0.777 ** 0.807 ** 1 0.846 ** 0.755 ** 0.838 ** 0.837 ** 0.807 ** 0.687 ** 0.800 ** 0.813 ** 0.814 ** 0.604 ** 0.620 ** 0.748 ** 0.859 ** 0.749 **
EGAT study 0.761 ** 0.832 ** 0.629 ** 0.814 ** 0.854 ** 0.846 ** 1 0.733 ** 0.752 ** 0.809 ** 0.866 ** 0.669 ** 0.786 ** 0.801 ** 0.663 ** 0.534 ** 0.600 ** 0.634 ** 0.817 ** 0.609 **
Omani score 0.680 ** 0.881 ** 0.519 ** 0.754 ** 0.854 ** 0.755 ** 0.733 ** 1 0.730 ** 0.836 ** 0.743 ** 0.581 ** 0.715 ** 0.613 ** 0.804 ** 0.565 ** 0.604 ** 0.577 ** 0.747 ** 0.554 **
IDRS 0.668 ** 0.866 ** 0.562 ** 0.794 ** 0.820 ** 0.838 ** 0.752 ** 0.730 ** 1 0.851 ** 0.806 ** 0.631 ** 0.830 ** 0.761 ** 0.784 ** 0.580 ** 0.651 ** 0.650 ** 0.787 ** 0.645 **
NUDS study 0.710 ** 0.911 ** 0.522 ** 0.823 ** 0.893 ** 0.837 ** 0.809 ** 0.836 ** 0.851 ** 1 0.797 ** 0.627 ** 0.787 ** 0.720 ** 0.755 ** 0.586 ** 0.641 ** 0.640 ** 0.813 ** 0.595 **
MJLPD study 0.780 ** 0.851 ** 0.712 ** 0.848 ** 0.846 ** 0.807 ** 0.866 ** 0.743 ** 0.806 ** 0.797 ** 1 0.695 ** 0.857 ** 0.887 ** 0.667 ** 0.551 ** 0.667 ** 0.644 ** 0.855 ** 0.594 **
Chinese DRS 0.574 ** 0.659 ** 0.535 ** 0.639 ** 0.642 ** 0.687 ** 0.669 ** 0.581 ** 0.631 ** 0.627 ** 0.695 ** 1 0.704 ** 0.680 ** 0.698 ** 0.610 ** 0.679 ** 0.788 ** 0.681 ** 0.650 **
Hisayama study 0.807 ** 0.831 ** 0.711 ** 0.865 ** 0.793 ** 0.800 ** 0.786 ** 0.715 ** 0.830 ** 0.787 ** 0.857 ** 0.704 ** 1 0.916 ** 0.686 ** 0.537 ** 0.663 ** 0.675 ** 0.811 ** 0.602 **
AUSDRISK 0.862 ** 0.777 ** 0.775 ** 0.838 ** 0.736 ** 0.813 ** 0.801 ** 0.613 ** 0.761 ** 0.720 ** 0.887 ** 0.680 ** 0.916 ** 1 0.590 ** 0.505 ** 0.631 ** 0.666 ** 0.846 ** 0.611 **
ITD 0.591 ** 0.826 ** 0.464 ** 0.683 ** 0.767 ** 0.814 ** 0.663 ** 0.804 ** 0.784 ** 0.755 ** 0.667 ** 0.698 ** 0.686 ** 0.590 ** 1 0.619 ** 0.603 ** 0.760 ** 0.695 ** 0.695 **
ARIC 0.500 ** 0.595 ** 0.412 ** 0.560 ** 0.592 ** 0.604 ** 0.534 ** 0.565 ** 0.580 ** 0.586 ** 0.551 ** 0.610 ** 0.537 ** 0.505 ** 0.619 ** 1 0.904 ** 0.623 ** 0.599 ** 0.632 **
San Antonio 0.579 ** 0.691 ** 0.443 ** 0.705 ** 0.694 ** 0.620 ** 0.600 ** 0.604 ** 0.651 ** 0.641 ** 0.667 ** 0.679 ** 0.663 ** 0.631 ** 0.603 ** 0.904 ** 1 0.673 ** 0.725 ** 0.706 **
Framingham
offspring 0.585 ** 0.691 ** 0.481 ** 0.644 ** 0.638 ** 0.748 ** 0.634 ** 0.577 ** 0.650 ** 0.640 ** 0.644 ** 0.788 ** 0.675 ** 0.666 ** 0.760 ** 0.623 ** 0.673 ** 1 0.676 ** 0.757 **
DPoRT 0.829 ** 0.894 ** 0.598 ** 0.864 ** 0.853 ** 0.859 ** 0.817 ** 0.747 ** 0.787 ** 0.813 ** 0.855 ** 0.681 ** 0.811 ** 0.846 ** 0.695 ** 0.599 ** 0.725 ** 0.676 ** 1 0.644 **
ARIC enhanced 0.616 ** 0.609 ** 0.519 ** 0.560 ** 0.582 ** 0.749 ** 0.609 ** 0.554 ** 0.645 ** 0.595 ** 0.594 ** 0.650 ** 0.602 ** 0.611 ** 0.695 ** 0.632 ** 0.706 ** 0.757 ** 0.644 ** 1
** p < 0.001; DETECT-2: Diabetes and Impaired Glucose Tolerance; DDRS: Danish Diabetes Risk Score; DESIR: Data from the Epidemiological Study on the Insulin Resistance Syndrome;
Cambridge: Cambridge Risk Score; QDScore: Qresearch Database Score; FINDRISC: Finnish Diabetes Risk Score risk; EGATS: Electric Generating Authority of Thailand Study; IDRS: The
Indian Diabetes Risk Score; NUDS: National Urban Diabetes Survey; MJLPD: MJ Longitudinal health-check-up-based Population Database; Chinese-DRS: Chinese Diabetes Risk Score;
AUSDRISK: Australian Type 2 Diabetes RISK; ITD: Instrument for type 2 diabetes; ARIC: Atherosclerosis Risk in Communities; San Antonio: San Antonio prediction model; Framingham
offspring: Framingham Offspring Score; DPoRT: Diabetes Population Risk Tool.
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Table 5. Agreement (kappa) between risk predicted (high and non-high risk) by DETECT-2, DDRS, FINDRISC, EGATS, and NUDS scores.
DETECT-2 DDRS Cambridge FINDRISC EGATS NUDS Hisayama AUSDRISK ITD ARIC
DETECT-2 NA 0.501 0.564 0.654 0.497 0.277 0.432 0.531 0.222 0.518
DDRS 0.501 NA 0.638 0.518 0.473 0.293 0.327 0.395 0.271 0.298
Cambridge 0.564 0.638 NA 0.555 0.633 0.414 0.541 0.524 0.187 0.293
FINDRISC 0.654 0.518 0.555 NA 0.664 0.399 0.480 0.645 0.193 0.358
EGATS 0.497 0.473 0.633 0.664 NA 0.562 0.624 0.713 0.121 0.249
NUDS 0.277 0.293 0.414 0.399 0.562 NA 0.540 0.444 0.067 0.123
Hisayama 0.432 0.327 0.541 0.480 0.624 0.540 NA 0.722 0.110 0.240
AUSDRISK 0.531 0.395 0.524 0.645 0.713 0.444 0.722 NA 0.133 0.316
ITD 0.222 0.271 0.187 0.193 0.121 0.067 0.110 0.133 NA 0.281
ARIC 0.518 0.298 0.293 0.358 0.249 0.123 0.240 0.316 0.281 NA
DETECT-2: Diabetes and Impaired Glucose Tolerance; DDRS: Danish diabetes Risk score; Cambridge: Cambridge Risk Score; FIDRISC: Finnish Diabetes Risk Score risk; EGATS: Electric
Generating Authority of Thailand Study; NUDS, National Urban Diabetes Survey; Hisayama: Hisayama study; AUSDRISK: Australian Type 2 Diabetes RISK; ITD: Instrument for type 2
diabetes; ARIC: Atherosclerosis Risk in Communities. NA: Non-Applicable.
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4. Discussion
There is great variability between risk prediction models for developing T2D. These prediction
models include a wide range of clinical variables and conventional biomarkers, from the most simple
models including only age, waist circumference, parental history of diabetes, and physical exercise
practice [41], to the most complex including also dietary characteristics [16,46,47], social deprivation
measures [31], educational level [48], and ethnicity [31,34,37,39].
The most commonly used risk predictors were age, BMI or obesity, family history of diabetes, and
hypertension. There were differences in the weight of the risk predictors included in the equation,
the adjusted odds ratio of obesity for undiagnosed T2D varied when comparing different countries
from North Europe such as Denmark (≤30 kg/m2 vs. <25 kg/m2) 4.4 (2.6–7.3) [28] and Finland 2.99
(1.31–6.81) [32] to those from Asia such as Thailand (≤27,5 kg/m2 vs. 23 kg/m2) 1.74 (1.17–2.60) [33], and
China (≤28 kg/m2 vs. 24 kg/m2) 1.56 (1.03–2.38) [44]. As it can be observed, there were differences in
the BMI cut-off point for obesity, which was lower in Asian populations. The prevalence of a risk factor
such as obesity and the cut-off points also differed, ranging from 16.3% (≤30 kg/m2) in Demark [28] to
6.3% (≤27.5 kg/m2) in the derivation cohort from the EGAT study in Thailand [33].
In the present cross-sectional study, the scores of the retrieved prediction equations as well as the
Spearman coefficients for the correlations between them were calculated. In the Caucasian population
considered, no higher correlations were found between the scores derived from Caucasians and the
ones derived from other ethnic groups, prevalence of diabetes, estimated cut-off points or country
proximity. However, higher correlations were found between the scores that included only clinical
variables than between those that included clinical and conventional biomarkers. Furthermore, higher
correlations were found between models that included only hypertension as risk predictors of T2D
than between those that included several cardiovascular risk factors (systolic and diastolic blood
pressure, cholesterol, triglyceride levels, etc.) There is also poor agreement when models derived from
“special populations” such as volunteers [29], Chinese living in Taiwan [42], or military officers [44]
were considered.
The percentage of people classified as high risk ranged from 3.1% [35] to 47.1% [54]. These
differences could be due to the fact that the cut-off point to classify people at high risk of developing
T2D is clearly related to the incidence of diabetes which, in the studies considered, ranged from 1.3% in
an adult population in the UK [30] to 26.6% in a Chinese population of military officers in Beijing [44].
Our study suggests that when highly diverse diabetes incidence and ethnicity derived risk
predictor models were applied in a Caucasian worker population, poor agreements were achieved.
Furthermore, differences in people classified as at high risk were also observed. Agreement did
not improve by prevalence of diabetes or country proximity. However, in a validation cohort in
a worldwide population (Africa, Asia, Oceania, North America, and Europe) [20], the area under
the curve of white Caucasian population behaved similarly, and showed a better prediction between
geographically closer countries, showing lower specificity when European developed risk prediction
models were applied to African or Asian populations.
Agreement between models did not improve when ethnicity was considered in the models. In this
regard, Tanamas [74], in a multi-ethnic cohort validation of highly diverse ethnicity development
predictive models, showed a modest influence of the ethnicity in the development cohort in the
prediction but there was no evidence that models performed better in populations with a similarity
between the development derivation ethnicity and the ethnics in the validation cohort. In this sense,
Rosella [24] in a multi-ethnic cohort showed that adding ethnicity did not improve discrimination
or the accuracy of predictive models. The causes of the ethnic differences in T2D incidence are not
well known. Specifically, the relative contributions of genetic and environmental factors to such
differences are largely unknown. Only a few studies in isolated populations have shown evidence
on how differences in frequencies of known T2D susceptibility genetic alleles account for ethnic
differences [75]. However, research for genetic susceptibility has not been uniform among the world’s
ethnic groups. Actually, ethnicity is associated with many other risk factors for T2D that may account
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for the race/ethnic differences in risk of T2D. These factors include, among others, obesity or overweight,
prediabetes condition, diet characteristics, socioeconomic status, area of residence, and environmental
contaminants [75,76]. An improved understanding of the impact of these factors on T2D risk should
lead to more effective preventive strategies. Performing better designed research must be a goal to
understand the ethnic related risk for T2D. Belonging to similar ethnicities or showing similar T2D risk
could not be the best way of ascertaining whether a model will perform properly in another population.
Although from the individual risk perspective, ethnicity information could be important, when
predicting new cases of diabetes at the population level, detailed ethnic information has not been
shown to improve discrimination and accuracy of the model or to identify a significant higher number
of diabetics in the population. Therefore, it could be more important to develop models using
measurements highly reproducible and available in the clinical practice.
Limitations
Our systematic review was limited to English, Portuguese, and Spanish language articles; therefore,
we may have missed some useful studies. We would like to emphasize that the purpose of the study
was to highlight the heterogeneity of the risk of developing diabetes in this population when using
different risk prediction models. It was not possible to validate this onset of disease in participants in
the present study since they were not followed up.
5. Conclusions
Numerous T2D prediction models exist based on readily available health data and provide an
adequate but not perfect estimate of the chance of developing T2D in the future. The systematic review
of 26 predictive models highlights a great heterogeneity in the risk predictors included and the cut-off
points of some risk predictors. A poor reporting of the development procedure of the risk prediction
models in terms of describing the data and providing sufficient detail in all steps taking in building
the model has been observed. Furthermore, most of the models have not been externally validated.
Ethnicity includes intrinsically important genetic and environmental factors related to diabetes onset;
however, the evidence is still controversial as regards the influence of ethnicity as an independent risk
predictor for T2D onset. Risk prediction models should be derived from the general population and
further research is required to improve prediction of T2D.
Differences in diabetes incidence, prevalence, and weight of risk factors seem to account for
the agreement differences between scores. In the Caucasian population of workers considered in
the present study there is better agreement between the multi-ethnic derivate score (DETECT-2) and
European derivate scores. Risk models development should change towards the use of more available
and reproductible risk predictors.
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